COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

ONE-SHOT Trial - Ultra-hypofractionated Single-dose SBRT for Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03294889
Recruitment Status : Recruiting
First Posted : September 27, 2017
Last Update Posted : May 14, 2020
Humanitas Hospital, Italy
University of Zurich
Kantonsspital Graubünden
Information provided by (Responsible Party):
Thomas Zilli, University Hospital, Geneva

Brief Summary:
The main objective of the phase I/II trial is to determine the safety and efficacy of a single fraction SBRT at a dose of 19 Gy in patients with localized prostate cancer.

Condition or disease Intervention/treatment Phase
Prostate Cancer Radiation: Stereotactic body radition (SBRT) Phase 1 Phase 2

Detailed Description:

Total dose and dose per fraction play an important role in the curative treatment of prostate cancer with radiotherapy (RT). Modern image guided external RT allows safe dose escalation of prostate cancer. There are strong radiobiological and clinical considerations that suggest that treatment with a small number of large fractions (hypofractionation) may increase the therapeutic ratio of RT for prostate cancer by increasing the tumor cell killing effect with relatively less toxic effect on the surrounding late responding normal tissues compared to conventional fractionation.

The question of how far can the number of fractions with SBRT be reduced is an exciting research matter with an undoubtful goal, face the challenge of assessing the potential for cure of prostate cancer patients with a single and unique fraction of high dose irradiation similar to what is already undertaken with radiosurgery against brain, lung, and liver targets.

We hypothesize that an ultra-hypofractionated single-dose SBRT employing state of the art of image-guided RT techniques may be feasible, with a safe toxicity profile and an optimal long-term tumor control. Hence, a prospective phase I/II clinical trial will be initiated in prostate cancer patients with a localized disease to validate this treatment schedule as an alternative to normofractionated/moderate hypofractionated RT schedules to be tested in a second time in a phase III trial.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 45 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: ONE-SHOT - Single Shot Radiotherapy for Localized Prostate Cancer. A Multicenter, Single Arm, Phase I/II Trial
Actual Study Start Date : September 1, 2017
Estimated Primary Completion Date : October 1, 2022
Estimated Study Completion Date : October 1, 2030

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Intervention Details:
  • Radiation: Stereotactic body radition (SBRT)

    Ultra-hypofractionated single-fraction SBRT with urethra-sparing with image-guidance and intra-fractional control motion with the Calypso® system.

    • 19 Gy in a single fraction to the whole prostate gland ± proximal seminal vesicles
    • 17 Gy in a single fraction to the urethra planning-risk volume (PRV)

Primary Outcome Measures :
  1. Clinical performance [ Time Frame: 3 months ]
    Toxicity will be evaluated using Grade ≥ 3 genitourinary and/or gastrointestinal acute adverse event (AE) during the first 3 month according to CTCAE classification v.4.03 (Phase I).

  2. Progression free survival (PFS) [ Time Frame: 3 years ]
    The primary endpoint is 3-years biochemical relapse free survival (bRFS). bRFS and its 97.5% one-sided confidence interval (CI) will be determined using the Kaplan Meier method. If the expected value of 96% isn't included in this interval, the efficacy of the experimental treatment will be questioned. (Phase II).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Histologically confirmed adenocarcinoma of the prostate
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Written informed consent according to ICH/GCP regulations before registration and prior to any trial specific procedures
  • Histologically confirmed adenocarcinoma of the prostate without small cell features
  • Tumor clinical stage cT1c-2c, pN0 or cN0, M0, according to UICC TNM 2009
  • MRI staging must confirm American Joint Committee on Cancer (AJCC) stage T1, T2a, T2b or T2c
  • Gleason score at biopsy 3+3 or 3+4 (WHO 2016 Grade Groups 1, 2)
  • PSA ≤15 ng/ml
  • WHO performance status 0-1
  • International Prostate Symptom Score ≤ 10 (alpha blockers allowed)
  • MRI-based volume estimation of prostate gland ≤ 70 cc
  • Patient agrees not to father a child during trial treatment and during 6 months thereafter

Exclusion Criteria:

  • Tumor clinical stage cT3a-3b or T4
  • Evidence of T3a, T3b or T4 disease as assessed by MRI
  • Positive lymph-nodes or metastatic disease from prostate cancer on imaging studies.
  • Significant tumor on the transitional zone as assessed by MRI
  • Gleason at biopsy ≥ 4+3
  • Androgen deprivation therapy or products known to affect PSA levels
  • Impossibility to implant Calypso beacons
  • History of hematologic or primary solid tumor malignancy, unless in remission for at least 3 years from registration with the exception of curatively treated localized non-melanoma skin cancer
  • Prior pelvic radiotherapy
  • Previous surgery for prostate cancer
  • Previous transurethral resection of the prostate (TURP) (< 12 weeks before registration)
  • Hip prosthesis
  • Severe or active co-morbidity likely to impact on the advisability of SBRT
  • Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the investigator may interfere with the planned staging, treatment and follow-up, affect patient compliance or place the patient at high risk from treatment-related complications

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03294889

Layout table for location contacts
Contact: Thomas Zilli, MD +41 79 55 32 563
Contact: Laurence Zulianello, PhD + 22 372 72 05

Layout table for location information
University Hospital of Geneva Recruiting
Genève, Switzerland, 1205
Contact: Thomas Zilli, MD    +41 79 55 32 563   
Contact: Laurence Zulianello, PhD    + 41 22 372 7205   
Sub-Investigator: Giorgio Lamana, MD         
Sub-Investigator: Yves Chalandon, MD         
Sponsors and Collaborators
University Hospital, Geneva
Humanitas Hospital, Italy
University of Zurich
Kantonsspital Graubünden
Layout table for investigator information
Principal Investigator: Thomas Zilli, MD University Hospital, Geneva
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Thomas Zilli, Médecin Adjoint Agrégé, University Hospital, Geneva Identifier: NCT03294889    
Other Study ID Numbers: 2017-01236
First Posted: September 27, 2017    Key Record Dates
Last Update Posted: May 14, 2020
Last Verified: May 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Thomas Zilli, University Hospital, Geneva:
Prostate cancer
Stereotactic body radiation therapy
Calypso® beacon system
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Prostatic Diseases